

Eagle Pharmaceuticals Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 19-Jan-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 16

[Return to Table of Contents](#)

Eagle Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Eagle Pharmaceuticals Inc
Parent Company Name	Eagle Pharmaceuticals Inc
Website	http://www.eagleus.com/
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	3
Number of Patents as Owner	11
Number of Patents as Third Party	0
Number of Deals	9
Key Indications	Cancer,Non-Hodgkin lymphoma,Chronic lymphocytic leukemia,Hyperthermia,Mesothelioma,Thrombosis,Malignant hyperthermia,Metastatic non small cell lung cancer,B-cell lymphoma,Acute myelogenous leukemia,Bacterial endocarditis,Bacterial infection,Bacterial skin infection,Congestive heart failure,Enterococcus faecalis infection,MRSA infection,Myelodysplastic syndrome,Non-small-cell lung cancer,Renal insufficiency,Sepsis,Staphylococcus aureus infection,Streptococcus agalactiae infection,Streptococcus infection,Streptococcus pyogenes infection
Key Target-based Actions	Factor IIa antagonist,PARP modulator,DHFR inhibitor,Thymidylate synthase inhibitor,Transferase inhibitor,DNA methyltransferase inhibitor,Ryanodine receptor antagonist
Key Technologies	Intravenous formulation,Small molecule therapeutic,Infusion,Peptide,Biological therapeutic,Nanoparticle formulation injectable,Suspension,Formulation preservation,Liquid formulation,Injectable formulation

COMPANY PROFILE

SUMMARY

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company, founded in 2007, which develops improved formulations of injectable products.

LICENSING AGREEMENTS

In September 2009, The Medicines Company licensed rights in the US and Canada to a ready-to-use formulation of argatroban from Eagle Pharmaceuticals. The formulation was under review by the FDA. Eagle would receive \$5 million up front in cash, and The Medicines Company would make a \$2 million equity investment in Eagle. Eagle could also receive milestones and royalties.

FINANCIAL

By May 2014, a one-for-6.41 reverse stock split of the company's common stock, and all outstanding shares of preferred stock converted into 7,487,928 million shares of common stock, had been approved by the company's board of directors. And also, all series C preferred stock warrants outstanding have been exercised for 34,074 shares of common stock.

In February 2014, the company planned to issue 3.35 million shares of common stock through an initial public offering at a price of \$15 per share and underwriters were granted 30-day option to purchase additional 502,500 shares of common stock. The Offering was expected to close on February 18, 2014. At that time, the shares were expected to be traded under the ticker symbol "EGRX".

[Return to Table of Contents](#)



COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	15.84
Change (USD)	0.49 (3.19%)
Previous Close Price (USD)	15.35
Volume	64,118
52-Week High (USD)	18.80
52-Week Low (USD)	9.16
Date	16-Jan-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	14,020,133
Current Market Capitalization	222,078,907
EPS (Date Reported)	

STOCK PERFORMANCE




MAJOR SHAREHOLDERS

[Return to Table of Contents](#)

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Park West Asset Management LLC	Hedge Fund	United States	711,606	5.07	44,144	0.07	10-Nov-2014
AllianzGI Wellness Fund	Mutual Fund	United States	99,384	0.71	0	0	30-Nov-2014
Carnegie Global Healthcare Fund	Mutual Fund	Sweden	94,407	0.67	-45,593	-0.33	30-Nov-2014
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	26,985	0.19	0	0	30-Nov-2014
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	25,754	0.18	0	0	30-Nov-2014
Thomson Horstmann & Bryant, Inc.	Investment Advisor/Hedge Fund	United States	19,632	0.14	19,632	1	30-Nov-2014
Thomson Horstmann & Bryant Microcap Fund	Mutual Fund	United States	19,632	0.14	19,632	1	30-Nov-2014
Vanguard Extended Market Index Fund	Mutual Fund	United States	6,547	0.05	300	0.05	30-Nov-2014
iShares Micro-Cap ETF	Mutual Fund	United States	3,231	0.02	3,231	1	31-Dec-2014
Fidelity NASDAQ Composite Index Fund	Mutual Fund	United States	2,942	0.02	0	0	30-Nov-2014
Fidelity NASDAQ Composite Index Tracking Stock	Mutual Fund	United States	1,248	0.01	52	0.04	31-Oct-2014
Guggenheim Investments	Investment Advisor/Hedge Fund	United States	943	0.01	216	0.3	31-Dec-2014
BMO Micro-Cap Fund	Mutual Fund	United States	951	0.01	-29	-0.03	30-Nov-2014
Wilshire Micro-Cap ETF	Mutual Fund	United States	943	0.01	216	0.3	30-Nov-2014
AXA/Lord Abbett Micro Cap Portfolio	Mutual Fund	United States	601	0	0	0	30-Nov-2014

[Return to Table of Contents](#)



	2013	2011	2012	2014	
Sales (USD M)	13.678903	9.525946	2.539402	19.099	
Operating Income (USD M)	-8.455124	-5.526865	-19.830738	-18.757	
Net Income (USD M)	-6.048473	-5.15049	-19.382641	-17.977	

Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	2.810793	-9.106132	-9.103385
2014 Q3	5.791876	-2.982398	-2.934079
2014 Q2	5.004766	-3.603016	-3.218172
2014 Q1	5.491565	-3.065454	-4.387364
2013 Q4	4.639974	-2.531285	-0.648881
2013 Q1	1.483066	-2.877475	-3.301619
2012 Q4	1.306041	-3.917659	-5.196355

BALANCE SHEET

Assets (USD M)

	2011	2012	2013	2014
Cash & Short Term Investments	12.600041	6.566886	10.455565	42.721
Inventories - Total	1.138936	0.086881	0	1.294
Current Assets - Total	14.762767	8.864997	17.482407	53.022
Property, Plant And Equipment - Net	0.704229	0.496731	0.402286	0.344
Other Assets - Total	0.095171	0.07632	0.217927	0.045
Total Assets	15.562167	9.438048	18.10262	53.411

Liabilities (USD M)

	2011	2012	2013	2014
Accounts Payable	1.537509	1.443838	1.1926	4.059
Short Term Debt & Current Portion Of Long Term Debt	0	8.571877	0	0
Current Liabilities - Total	9.30814	20.881559	14.341805	20.315
Long Term Debt	0	0	0	0
Deferred Taxes	0	0	0	
Other Liabilities	0.025852	0.654527	1.706829	0
Total Liabilities	9.333992	21.536086	16.048634	20.315

[Return to Table of Contents](#)



Stockholders Equity (USD M)

	2011	2012	2013	2014	
Minority Interest	0	0	0	0	
Preferred Stock	77.402857	81.335894	89.983	0	
Common Stock	0.010906	0.010595	0.003048	0.014	
Treasury Stock	0				
Total Liabilities & Shareholders' Equity	15.562167	9.438048	18.10262	53.411	

FORECASTS

EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.35	-0.97	-0.97
31-Dec-2016	3.75	3.72	3.72
31-Dec-2017	4.56	4.44	4.26

Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0		-19.22	26.7
31-Dec-2016	0		64.03	149.04
31-Dec-2017	0		107.59	235.45


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	1	4
Hematological disease	2	1	3
Respiratory disease	1	1	2
Cardiovascular disease	1	0	1
Immune disorder	1	0	1
Temperature disorder	1	0	1
Infectious disease	0	1	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Registered	2
Discovery	3
Discontinued	1
No Development Reported	2

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Patent - Exclusive Rights	0	0	3	0	3
Drug - Development/Commercialization License	1	0	2	0	3
Drug - Manufacturing/Supply	0	0	1	0	1
Technology - Delivery/Formulation	0	0	1	0	1

CLINICAL TRIALS

[Return to Table of Contents](#)

Trials by Condition Studied

Condition Studied	Ongoing	All
Gastrointestinal disease	0	1
Hematological disease	0	1
Neoplasm	0	1
Inflammatory disease	0	1
Immune disorder	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	0	1
Phase 1	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	5	0	5
Endocrine disease	1	0	1
Gastrointestinal disease	1	0	1
Genitourinary disease	2	0	2
Hematological disease	5	0	5
Immune disorder	2	0	2
Neoplasm	6	0	6
Neurological disease	2	0	2
Respiratory disease	2	0	2
Infectious disease	1	0	1

[Return to Table of Contents](#)



Injury	2	0	2
Inflammatory disease	1	0	1
Gynecology and obstetrics	1	0	1
Temperature disorder	2	0	2
Dermatological disease	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

dantrolene sodium (heat stroke/malignant hyperthermia), Eagle Pharmaceuticals

Drug Name	dantrolene sodium (heat stroke/malignant hyperthermia), Eagle Pharmaceuticals
Key Synonyms	dantrolene sodium, dantrolene, Ryanodex
Originator Company	Eagle Pharmaceuticals Inc
Active Companies	Eagle Pharmaceuticals Inc
Inactive Companies	
Highest Status	Registered
Active Indications	Malignant hyperthermia, Hyperthermia
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Nanoparticle formulation injectable, Intravenous formulation, Suspension, Small molecule therapeutic
Last Change Date	09-Jan-2015

ready-to-dilute bendamustine hydrochloride (iv, chronic lymphocytic leukemia/non-Hodgkin's lymphoma), Eagle Pharmaceuticals

Drug Name	ready-to-dilute bendamustine hydrochloride (iv, chronic lymphocytic leukemia/non-Hodgkin's lymphoma), Eagle Pharmaceuticals
Key Synonyms	bendamustine
Originator Company	Eagle Pharmaceuticals Inc
Active Companies	Eagle Pharmaceuticals Inc
Inactive Companies	
Highest Status	Registered
Active Indications	Chronic lymphocytic leukemia, Non-Hodgkin lymphoma
Target-based Actions	PARP modulator
Other Actions	Anticancer alkylating agent
Technologies	Intravenous formulation, Infusion, Small molecule therapeutic
Last Change Date	18-Dec-2014

[Return to Table of Contents](#)



undisclosed compounds (cancer), SciDose/Eagle Pharmaceuticals

Drug Name	undisclosed compounds (cancer), SciDose/Eagle Pharmaceuticals
Key Synonyms	
Originator Company	SciDose LLC
Active Companies	Eagle Pharmaceuticals Inc, SciDose LLC
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Unspecified drug target, Anticancer
Technologies	Small molecule therapeutic
Last Change Date	04-Jul-2014

ready-to-use bivalirudin (iv, thrombosis in percutaneous transluminal angioplasty), Eagle Pharmaceuticals

Drug Name	ready-to-use bivalirudin (iv, thrombosis in percutaneous transluminal angioplasty), Eagle Pharmaceuticals
Key Synonyms	bivalirudin
Originator Company	Eagle Pharmaceuticals Inc
Active Companies	Eagle Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Thrombosis
Target-based Actions	Factor IIa antagonist
Other Actions	Coagulation inhibitor, Hirudin modulator
Technologies	Intravenous formulation, Biological therapeutic, Peptide
Last Change Date	12-Aug-2014

[Return to Table of Contents](#)



ready-to-dilute pemetrexed (iv, non-small cell lung cancer/mesothelioma), Eagle Pharmaceuticals

Drug Name	ready-to-dilute pemetrexed (iv, non-small cell lung cancer/mesothelioma), Eagle Pharmaceuticals
Key Synonyms	pemetrexed
Originator Company	Eagle Pharmaceuticals Inc
Active Companies	Eagle Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Metastatic non small cell lung cancer, Mesothelioma
Target-based Actions	DHFR inhibitor, Thymidylate synthase inhibitor, Transferase inhibitor
Other Actions	Anticancer antimetabolite
Technologies	Intravenous formulation, Infusion, Small molecule therapeutic
Last Change Date	09-Apr-2014

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)